Studying the association of the Sprouty gene expression with clinical parameters of HCC, they indicated that the expression of Spry2 was significantly lower in patients with advanced disease and angiolymphatic invasion, whereas Spry1 was significantly upregulated in cases without underlying cirrhosis compared with cirrhotic patients. This evidence concerns the gene SPRY2 and hepatocellular carcinoma.